Early-Stage Resectable Non-Small Cell Lung CancerPhase 1NCT06566443Papers
Honokiol
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
What the film says
Mesothelioma grows in the lining of the chest, usually decades after breathing asbestos. Most people live one to two years after diagnosis.
Its cells are coated in a protein called mesothelin, which also marks many pancreatic, ovarian, and lung cancers. CAR T cells aimed at mesothelin have mostly fallen short.
The idea: grip the target closer to the cell, with younger cells.
Earlier receptors grabbed mesothelin at its far tip. This one binds near the membrane, and in the lab that meant more killing and longer-lived T cells. The cells are also drawn from the youngest, stem-like T cells, slower to exhaust.
Raffit Hassan leads it at the NIH Clinical Center, in adults whose tumors carry mesothelin. Safety first. Public record; not medical advice.
Sources behind this film
Lining of the chest; asbestos decades earlier; median survival 1–2 years; Mesothelin on mesothelioma and many pancreatic, ovarian, lung, gastric, colorectal, thymic cancers; Earlier mesothelin CAR T trials "have not resulted in significant anti-tumor efficacy"; hYP218 binds the membrane-proximal region; increased killing and persistence preclinically (+2 more lines)
Tomar S. Mol Cancer Ther, 2022
hYP218 binds the membrane-proximal region; increased killing and persistence preclinically
The drug
Variable doses, administered intravenously on Day 0
Assay done at screening to determine mesothelin expression levels
Background: * Mesothelin (MSLN), a cell surface glycoprotein, normally expressed on the mesothelial cells lining the pleura, peritoneum, and pericardium, is highly expressed in many cancers including mesothelioma, ovarian, lung, thymic, colorectal, pancreatic, and gastric cancers, making it an attractive target for immunotherapy. * Adoptive cell therapy using CAR T cells exploits the ability of these modified T cells to recognize and kill their target.
The study
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person s own immune cells (T cells); the T cells are genetically modified to target and kill tumor cells with high levels of MSLN.
Objective: To test a new treatment (TNhYP218 CAR T cells) in people with solid tumors including mesothelioma. Eligibility: People aged 18 and older with solid tumors including mesothelioma that returned or spread after standard treatment. Design: Participants will be screened. A small piece of tissue will be cut from a tumor (biopsy). The sample will be tested to see if it has enough MSLN.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.